SELLAS Regulatory Tuesday, November 17, 2026 +0.80 Positive

SELLAS Reports Positive Phase 3 AML Trial Data for Cancer Vaccine GPS

SELLAS Life Sciences announced statistically significant overall survival improvement in a Phase 3 AML trial of GPS. The result validates a potential breakthrough in oncology, driving significant market relevance for the biopharmaceutical.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed